Sandoz has started building for the future after it completes a planned spin-out from parent Novartis, with a major investment in a production plant in Slovenia for its bi
Novartis' soon-to-be-divested Sandoz unit has filed its proposed biosimilar of Amgen's osteoporosis therapy Prolia/Xgeva with the FDA, saying it is "among the first" to fi
With a separation from parent company Novartis now confirmed, Sandoz has moved to strengthen its revenue base with the acquisition of global rights to mainstay antifungal drug Mycamine from
The Reuters Pharma event 2022 began as a bustling industry affair yesterday, based out of the Nice Acropolis convention centre on France’s balmy south coast.
After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company.
Software that can be used to monitor patients with neurodegenerative disorder amyotrophic lateral sclerosis (ALS) using their voice patterns has been granted breakthrough